about
Lentiviral vectors in gene therapy: their current status and future potentialAntioxidant-based therapies for angiotensin II-associated cardiovascular diseasesDopamine increases glial cell line-derived neurotrophic factor in human fetal astrocytes.Comparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey (Macaca mulatta) brainsHIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1Investigation of molecular mechanism of chronic pain in the anterior cingulate cortex using genetically engineered miceThe attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase.Gene delivery to the spinal cord: comparison between lentiviral, adenoviral, and retroviral vector delivery systemsNeuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration.Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cellsGenetic therapy for pain management.Gene therapy in wound repair and regeneration.Diffusion and convection in collagen gels: implications for transport in the tumor interstitiumFrom gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system.Conditional gene expression systems in the transgenic rat brain.Neuroprotective gene therapy against acute neurological insults.Transcription factor Phox2 upregulates expression of norepinephrine transporter and dopamine β-hydroxylase in adult rat brainsTranscriptional Response of Human Neurospheres to Helper-Dependent CAV-2 Vectors Involves the Modulation of DNA Damage Response, Microtubule and Centromere Gene Groups.Gene transfer in tissue repair: status, challenges and future directions.Gene therapy and wound healingNeurodegeneration and cell replacement.The promise of gene therapy for the treatment of epilepsy.Imaging gene delivery with fluorescence microscopy.Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.Viral vectors for therapy of neurologic diseases.A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells.Transplants of cells genetically modified to express neurotrophin-3 rescue axotomized Clarke's nucleus neurons after spinal cord hemisection in adult rats.Insulators coupled to a minimal bidirectional tet cassette for tight regulation of rAAV-mediated gene transfer in the mammalian brain.Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS.Bcl-2 expression by retrograde transport of adenoviral vectors with Cre-loxP recombination system in motor neurons of mutant SOD1 transgenic mice.Syngeneic central nervous system transplantation of genetically transduced mature, adult astrocytes.Effect of immunity on gene delivery into anterior horn motor neurons by live attenuated herpes simplex virus vector.Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord.Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems.Antiapoptotic effect both in vivo and in vitro of A20 gene when transfected into rat hippocampal neurons.Tunable PEGylation of branch-type PEI/DNA polyplexes with a compromise of low cytotoxicity and high transgene expression: in vitro and in vivo gene delivery
P2860
Q24629462-C7233996-B364-40A9-A71D-D76160170E86Q27016563-7AFA83CB-3331-4067-ACCD-FD355657D57CQ31949243-1022D40B-889B-4577-937B-035815CFABEFQ33577391-92B5F1B9-4C71-4B57-ACCB-4338AA303BE9Q33671675-7B56D9FC-7491-4DED-A446-A475ACAF9D96Q33775263-962E964F-AA5B-45C2-A671-43934462F5A3Q33812130-D6C1C274-B627-4153-AEDD-A72A9E61FF6CQ33821596-4D58E7DB-5B35-4AC6-8B8C-384389CFB3ADQ33978310-6FFC2FB6-7A8C-49AA-9497-352344A12CDCQ34036114-611C4BDA-289E-41FB-9424-92F7E68C522AQ34074627-E2C7D220-1591-4F07-8148-3177B5C6ECC8Q34156741-42C33E70-70B5-472E-BCBF-D91DC7ED4F68Q34178741-60C6FE9C-9DCC-4C4D-B057-080844A5569AQ34224260-550F26B4-0C60-4784-86E9-7484DF4E34F2Q34401784-9456A162-D120-436B-B582-B6D8EB746125Q35038275-3AB1DDE6-D633-4BF2-9993-DD0EBEE03514Q35194612-75BD07B9-EB6C-4D87-9AC3-B310E108BC78Q35710695-950E0446-6986-4BED-B484-60EBC9043B34Q35873744-C34CBCB7-B5E1-446D-B613-D708A2258264Q36727410-56F15053-8267-4FB6-9A4A-5FBCAE01EE62Q36748869-7CF04A60-B950-4C32-B3A4-2EB53E9CC2ECQ37021317-563FF49A-2A77-42CE-BDB0-1A1C0A724D8DQ37038838-27A70718-70D3-4460-B936-9BBF3E73F5A3Q37416147-971DBAE7-AEA5-4E2C-851A-532EC7C5E5FEQ38746238-EF3F5782-810F-47DC-9EAA-5D74643B6BEFQ40608616-E738EFCC-0F9F-4250-83DA-3986D3564D39Q40781409-F0BB2D29-CE5C-4FF8-AD27-2C4E6123A42AQ42518623-80638051-22A1-4963-ACFC-88254DB1443CQ42525849-C1ABBEB0-CA18-4310-B9B3-2813911F7109Q43662965-E4B3E8D3-86E0-45FC-8FDD-FB8BFCE9A71BQ45193147-099E0598-0BD1-4583-AB74-5419C813C142Q45736046-4E3515DA-76C5-4CC8-A292-295492F11CE9Q45863310-9EA95ECD-26A3-4BC6-9CCE-E36F83657EDFQ45876651-FFB419BB-7A01-4690-ADF3-CC9B6804DF91Q45880642-57612BF8-CD0E-48B5-A569-072066721BC0Q57083402-A11C35A6-6DDB-46CF-9E6B-9298DE38CA3D
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Gene therapy in the CNS.
@ast
Gene therapy in the CNS.
@en
type
label
Gene therapy in the CNS.
@ast
Gene therapy in the CNS.
@en
prefLabel
Gene therapy in the CNS.
@ast
Gene therapy in the CNS.
@en
P2093
P2860
P356
P1433
P1476
Gene therapy in the CNS
@en
P2093
Bakowska JC
Breakefield XO
Costantini LC
P2860
P2888
P304
P356
10.1038/SJ.GT.3301119
P50
P577
2000-01-01T00:00:00Z